Real-World Use of Tafasitamab for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the United States by Age Group (>70 Years and ≤70 Years)
Hematology, Transfusion and Cell Therapy（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined